Awaiting development: Guidance and quality standards
Showing 1 to 3 of 3
| Title | Type |
|---|---|
| Bevacizumab (Avastin and biosimilars) with fluoropyrimidine-based chemotherapy for untreated metastatic colorectal cancer [ID6465] | Technology appraisal guidance |
| Denosumab biosimilar for Giant cell-rich tumours of bone or Skeletal events in bone malignancies ID12150 | Technology appraisal guidance |
| Golimumab biosimilar for Rheumatoid Arthritis, Juvenile Arthritis, Ankylosing Spondylitis, Axial Spondyloarthropathy, Psoriatic Arthritis, and Ulcerative Colitis [ID12208] | Technology appraisal guidance |